South African Medical News

Back to Home Page

Print using browser
Boehringer Ingelheim - Lendormin tablets (brotizolam)

boehringeringelheimlogo






Dear Healthcare Provider

Boehringer Ingelheim regrets to inform you that Lendormin tablets has been discontinued and will no longer be manufactured.

Boehringer Ingelheim currently have limited stock available which expires 12/2018 and will be withdrawn from their distributor in 08/2018.

* This is a drug - read the leaflet carefully before use. 


* Ask your doctor or pharmacist for further information. 


Boehringer Ingelheim apologise in advance for any inconvenience caused by this discontinuation and thank you for your continued support.

For full prescribing information please refer to package insert approved by the Medical Regulatory Authority.
 
Boehringer Ingelheim (Pty) Ltd, 407 Pine Ave, Randburg

S5 Lendormin 0,250 mg tablets. Each tablet contains brotizolam 0,250 mg. Reg. No. Q/2.2.297

You need to be logged in to see more details. Register Now!


Click here to visit the Boehringer Ingelheim website....
Contact: Francesco Martiradonna, National Key Accounts Manager
Telephone: +27 (0) 11 348 2400
E-mail: francesco.martiradonna@boehringer-ingelheim.com
Date: Wednesday, July 4, 2018